12th Jul 2016 05:58
LONDON (Alliance News) - Irish pharmaceuticals company Shire PLC late on Monday said the US Food & Drug Administration has approved its Xiidra dry eye treatment.
Shire said Xiidra is the only prescription eye drop indicated for the treatment of both signs and symptoms of dry eye disease, and it anticipates it will launch in the US in the third quarter of 2016.
"As Shire's first FDA-approved medicine in ophthalmics, this significant milestone advances our goal of becoming the global leader in this category, where there are unmet patient needs. We have a robust ophthalmics pipeline, and we look forward to leveraging Xiidra as our entree into the space as we continue to develop additional innovative eye care treatment options," said Flemming Ornskov, Shire's chief executive.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Shire